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Tumor suppressor p53 is a major cellular guardian
of genome integrity, and its inactivation is the most
frequent genetic alteration in cancer, rising up
to 80% in squamous cell carcinoma (SCC). By
adapting the small hairpin RNA (shRNA) technology,
we inactivated endogenous p53 in primary epithelial
cells from the epidermis of human skin. We show
that either loss of endogenous p53 or overexpres-
sion of a temperature-sensitive dominant-negative
conformation triggers a self-protective differentia-
tion response, resulting in cell stratification and
expulsion. These effects follow DNA damage and
exit from mitosis without cell division. p53 preserves
the proliferative potential of the stem cell compart-
ment and limits the power of proto-oncogene MYC
to drive cell cycle stress and differentiation. The
results provide insight into the role of p53 in self-
renewal homeostasis and help explain why p53
mutations do not initiate skin cancer but increase
the likelihood that cancer cells will appear.
INTRODUCTION
Mutations of tumor suppressor p53 are detected in 50% of hu-
man cancer and are associated with poor prognosis (http://
p53.free.fr; Petitjean et al., 2007). p53 is a transcription factor
with a major role in halting the cell cycle upon DNA damage, al-
lowing DNA repair and chromosomal integrity, its loss of function
often causing genomic instability (Di Leonardo et al., 1997; Tay-
lor and Stark, 2001; Aylon and Oren, 2011; Carvajal and Man-
fredi, 2013). For these reasons, it has been referred to as the
‘‘guardian of the genome’’ (Lane, 1992). p53 upregulates diverse
cell cycle inhibitors such as p21CIP1 or the 14-3-3 family.Cell ReConcomitantly, it induces MDM2, which by a negative loop pro-
motes p53 degradation. Most p53 mutations render it inactive,
avoiding degradation and resulting in protein accumulation
(Lane, 1992; Aylon and Oren, 2011). Insufficient DNA repair in
the presence of p53 can result in cell death via apoptosis (Yon-
ish-Rouach et al., 1991; Roos and Kaina, 2006; Aylon and
Oren, 2011).
Squamous cell carcinoma (SCC) is the most frequent human
malignancy. SCC of the skin is rapidly increasing worldwide,
especially in fair individuals (Rogers et al., 2010; http://seer.
cancer.gov). SCC tends to be aggressive and develop metas-
tasis, also in the skin (4%–5%; Karia et al., 2013), and due to
its high incidence, the associatedmortality is reaching significant
numbers. In the United States, SCC of the skin caused 4,000 to
8,000 deaths in 2012 (Karia et al., 2013). The frequency of p53
inactivation is strikingly high in skin SCC (over 80%; Shea
et al., 1992; Brash, 2006; http://p53.free.fr). This is mostly due
to the mutagenic effects of UV light (Jonason et al., 1996). Un-
derstanding the function of p53 in human epidermis provides
insight into its role in malignancy.
p53 has been reported to accumulate and mediate apoptosis
in the epidermis in response to sunburn (Hall et al., 1993; Ziegler
et al., 1994). However, the role of p53 in epidermal homeostasis
is not well understood, although it is detected in proliferative cells
and downregulated during differentiation (Woodworth et al.,
1993; Kallassy et al., 1998; Dazard et al., 2000). Studying this
issue has in part been hampered because the skin of p53
knockout mice appears unaffected (Donehower et al., 1992).
These mice develop spontaneous tumors and die mainly of
thymic lymphoma by 4–6 months of age. Intriguingly, during
this time, they do not develop skin carcinomas. The skin must
have powerful self-protective mechanisms, since patches or
‘‘columns’’ of cells containing mutated p53 have been frequently
reported in otherwise asymptomatic skin (Jonason et al., 1996;
Ren et al., 1997; le Pelletier et al., 2001). These mutations are
UV associated and do not lead to SCC, further indicating that
disruption of p53 in mouse skin alone is insufficient to driveports 9, 1349–1360, November 20, 2014 ª2014 The Authors 1349
skin epithelial cancer. Consistently, the absence of p53 does not
increase the number or growth rate of chemically induced benign
tumors but accelerates their progression to carcinoma (Kemp
et al., 1993). Accordingly, the rare human Li-Fraumeni inherited
syndrome, caused by heterozygous autosomal p53mutation, in-
volves spontaneous cancer excluding cutaneous carcinomas
(Malkin et al., 1990; Srivastava et al., 1990). Similarly, mice over-
expressing mutant p53 do not display higher rates of sponta-
neous skin carcinomas (Lavigueur et al., 1989; Harvey et al.,
1995). The mechanisms protecting the skin from loss of p53
remain intriguing (Kemp et al., 1993).
We have previously identified an epidermal checkpoint that re-
sponds to deregulated S phase of the cell cycle and DNA dam-
age by triggering terminal squamous differentiation (Gandarillas,
2012). This response involves mitotic bypass or slippage (failure
to maintain G2/M arrest, leading to defective exit of mitosis and
re-replication in the absence of cell division; Andreassen and
Margolis, 1994; Blagosklonny, 2007; Gandarillas, 2012). During
mitotic slippage, the nuclei can divide and return to G1 or not,
but cells stay in a special G2/M, unable to achieve cytokinesis
(Mantel et al., 2008; Zanet et al., 2010; Freije et al., 2012). Over-
expression of MYC or cyclin E triggers this mitosis-differentiation
checkpoint in human keratinocytes as an oncogene-induced dif-
ferentiation response (OID; Freije et al., 2012; Gandarillas, 2012).
It has been shown that overfunction of MYC and other onco-
genes can cause DNA damage (DNA strand breaks), and this
in turn induces p53-mediated apoptosis (Pusapati et al., 2006;
Halazonetis et al., 2008). Ectopic cyclin E in human keratinocytes
mediatesMYC-induced differentiation and causes accumulation
of DNA damage (Freije et al., 2012). In addition, MYC induces
p53 in keratinocytes as they commit to differentiation (Dazard
et al., 2000). Altogether, these results raise the possibility that
MYC might promote epidermal differentiation by causing DNA
damage, and this response might be mediated by p53. We
aimed to investigate this issue by suppressing p53 function in
human primary keratinocytes from different individuals, with or
without overactivation of MYC, by making use of three different
well-characterized small hairpin RNA (shRNA) constructs, a tem-
perature-sensitive mutant, and stratifying organotypic cultures.
The results reveal a human squamous differentiation mechanism
protecting self-renewal homeostasis against genetic damage.
RESULTS
Replication Stress Initiates MYC-Induced
Differentiation of Human Epidermal Keratinocytes
In order to determine whether MYC-induced keratinocyte differ-
entiation is mediated by DNA damage, we generated primary
keratinocytes isolated from human skin expressing a conditional
MYCER (HKMYCER). This fusion protein renders MYC activat-
able by 4-OH-tamoxifen (OHT; Littlewood et al., 1995). Activa-
tion of MYC by OHT in keratinocytes for 2 days induces the
cell cycle (Freije et al., 2012) and for 5 days promotes terminal
differentiation and polyploidy (Gandarillas and Watt, 1997; Gan-
darillas et al., 2000).
We compared the dynamics of DNA replication, p53 induction,
and DNAdamage after activation ofMYCER byOHT.We studied
this by measure of bromodeoxyuridine (BrdU) incorporation1350 Cell Reports 9, 1349–1360, November 20, 2014 ª2014 The Aut(DNA synthesis) and phosphorylation on serine 139 of histone
H2AX (gH2AX, a marker of DNA strand breaks; Rogakou et al.,
1998). Activation of MYC rapidly caused an increase of the pro-
portion of cells undergoing DNA replication (Figure 1A, BrdU
12h). This induced the p53/p21 pathway (Figures 1B, 1C, and
S1A), as reported previously (Dazard et al., 2000; Pusapati
et al., 2006), accumulation of cells in the G2/M phase of the
cell cycle (Figure 1A), and expression of cyclin A andmetaphasic
phosphohistone H3 (P-H3, strong at condensed chromosomes;
Figures 1C and S1B). The rapid activation of the cell cycle shortly
preceded an increase of the DNA damage marker gH2AX peak-
ing by 24 hr (Figures 1A and S1A). These changes are consistent
with cell cycle deregulation and replication stress leading to
DNA strand breaks (Bartkova et al., 2006). By 2 days, a striking
increase of nuclear and nucleolar size and binucleation followed
(Gandarillas et al., 2000; Figures 1B and S1A). These results
show that MYC causes DNA damage prior to increased differen-
tiation in human keratinocytes.
In keratinocytes, a mitosis block by genotoxic agents triggers
squamous differentiation (Gandarillas, 2012). To test whether
MYC at least in part might enhance differentiation by causing
irreparable DNA damage, we treated HKMYCER cells with
KU55933 (KU), a specific inhibitor of the DNA-break repair ataxia
telangiectasia mutated (ATM) pathway (Hickson et al., 2004).
Interestingly, treatment with KU augmented the power of MYC
to induce differentiation by 6 days, as measured by involucrin
expression (Figure 1D), suggesting that unrepaired DNA damage
contributes to MYC-induced keratinocyte differentiation. In
order to further test whether accumulation of DNA damage
and failure to complete DNA repair triggers a differentiation
response, we treated human keratinocytes with NU1025 (NU) a
specific inhibitor of the DNA repair poly(ADP-ribose)polymerase
(PARP; Griffin et al., 1995). Interestingly, treating keratinocytes
with NU caused accumulation of DNAdamage and subsequently
induced terminal differentiation as monitored by involucrin
expression and cell stratification (Figures 1E and S1C). These re-
sults provide evidence suggesting that a DNA damage-induced
differentiation response might be part of the normal program of
keratinocytes. Consistently, keratinocytes heavily labeled for
gH2AX were found stratifying into the differentiated layer (Fig-
ure S1D; Movie S1).
Inactivation of p53 Potentiates MYC-Induced
Differentiation
We aimed to investigate whether p53 mediates MYC-induced
keratinocyte differentiation as a response to replication stress.
To this end, we adapted shRNA technology for primary keratino-
cytes and knocked down endogenous p53 in the presence of
conditional MYC (MYCER). We have made use of three well-
characterized lentiviral constructs bearing p53 shRNA (see
Experimental Procedures; Kim et al., 2007; Rodriguez et al.,
2011; Sandler et al., 2011; from hereon shP53), one of which
(as its vector control) carries a gene for GFP. Figures 2A–2C
show the inhibition of endogenous p53 by immunofluorescence,
western blotting (protein), and RT-PCR (mRNA). Immunofluores-
cence analyses showed undetectable levels of p53 in individual
GFP-expressing cells shortly after infections (Figure 2A and
not shown). shP53 suppressed MYC induction of p53 and itshors
CE
D
A B Figure 1. DNA Damage Initiates MYC-
InducedDifferentiation of Human Epidermal
Keratinocytes
(A) Flow-cytometry quantitation of human kerati-
nocytes (HK) expressing conditional MYCER after
activation of MYC by OHT for the periods of time
indicated with respect to controls with no OHT
(CT): percent of cells undergoing DNA synthesis
(BrdU+, green), inG2/M (4N,DNAcontent, blue), or
expressing the DNA damage marker gH2AX (red).
(B) Immunostaining for p53 (green) in CT or after
activation of MYC for 48 hr. Nuclear DNA by DAPI
(blue). Arrows: large nuclei positive for p53. Scale
bar, 50 mM. See also Figure S1A.
(C) Expression of the cell cycle regulators indi-
cated in MYCER cells after activation of MYC as
indicated. Plots: quantitation of the western blots
normalized to the loading control housekeeping
protein GAPDH (GDH); CycA, cyclin A. See also
Figure S1B.
(D) Flow-cytometry quantitation of the epidermal
differentiation marker involucrin (Invol) in MYCER
cells untreated or treated with the ATM inhibitor
KU55933 (KU) for 6 days, as indicated.
(E) Effects of the inhibition of PARP repair poly-
merase in HK by treatment with NU1025 (NU) as
analyzed by western blot for gH2AX (left) or by
flow cytometry for Invol (large bar histogram,
right), for the periods indicated. Small bar histo-
gram is a quantitation of the gH2AX western blots
normalized to GDH. The Invol positive region was
determined by a negative isotype antibody control
(CD8). See also Figure S1C.
Error bars are SEM. Data are average of duplicate
samples of representative experiments. *p < 0.05.transcriptional target protein, p21CIP1 (p21; Figures 2A–2C). Un-
expectedly, the induction of differentiation 5 days after activation
of MYC was not attenuated but augmented in the presence of
shP53, as this provoked a higher rate of stratification, morpho-
logical changes, and expression of the terminal differentiation
markers involucrin and keratin K1 (Figures 2D–2G). Activation
of MYC and inactivation of p53 therefore cooperated in driving
cells toward differentiation. This indicates that in keratinocytes,
endogenous p53 does not mediate MYC-induced differentiation
but rather restrains it.
Inactivation of p53 in Human Normal Keratinocytes
Causes Replication Stress
Enhanced differentiation in HKMYCER after inhibition of p53
suggested that endogenous p53 opposes the action of MYC.
To explore the cell cycle mechanisms by which p53 functions,
we infected normal primary keratinocytes freshly isolated from
human skin with the three shP53 constructs. The shP53 con-
structs efficiently downregulated p53 even upon treatment with
the genotoxic drug doxorubicin (DOXO), which causes acute
DNA damage and strongly induces p53 (Figures 3A–3C and
S2A). In the absence of DOXO, western blotting and immunoflu-
orescence staining or RT-PCR showed barely detectable levels
of the endogenous protein or mRNA, respectively, 2 or 3 days af-
ter delivery of the shP53s (Figures 3B–3D and S2A). p53 target
p21CIP was also downregulated (Figures 3A, 3B, and S2A), indi-Cell Recating that both p53 protein and function were suppressed. We
first tested whether the loss of p53/p21 in human keratinocytes
might cause cell cycle deregulation and failure to repair DNA
breaks. Inhibition of p53 did not alter significantly the expression
of its related factor, p63 (Figure 3A), but provoked a rapid induc-
tion of cell cycle markers phospho-Rb, premitotic cyclin A, and
mitotic phosphohistone pH3 (Figures 3B, S3A, and S3B). Given
the reported capacity of p63 to induce cell cycle and epidermal
differentiationmolecules (Koster, 2010), it might contribute to the
observed effects.
Interestingly, the cell cycle changes caused by shP53 resulted
in increased DNA damage as measured by gH2AX foci (Fig-
ure 3B, 3D, and 3E). The induction of phospho-Rb and gH2AX
after inactivation of p53 was transient (Figures 3B and S5B).
Inactivation of p53 in keratinocytes therefore caused cell cycle
and replication stress as identified by S phase deregulation
and accumulation of DNA strand breaks.
Loss of p53 Provokes Mitotic Slippage and Loss of
Proliferative Potential
The early cell cycle activation upon suppression of p53 led to a
transient increase of DNA replication (BrdU incorporation; Fig-
ures 4A and S2B, 48 hr). Subsequently, the peak of BrdU-posi-
tive cells shifted from the diploid to the polyploid range (Figures
4A and S2B), thus indicating that some replicating cells lost the
capacity to divide. As a result, the cell cycle profile of the wholeports 9, 1349–1360, November 20, 2014 ª2014 The Authors 1351
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Figure 2. p53 Restrains MYC-Induced
Epidermal Differentiation
(A) Expression of GFP (green) and p53 (red) by
immunofluorescence of HKMYCER cells infected
with control vector CTGFP (CT) or with shP53 as
indicated after activation of MYC by addition of
OHT for 3 days. Note that within the mixed cul-
tures, p53 is undetected in cells expressing shP53
(green cells, broken line).
(B) Detection of p53 and its target p21 by western
blot in CT or shP53 cells treated with OHT for
3 days as indicated. Bar histograms represent
quantitation of the western blots normalized to
GAPDH (GDH).
(C) Expression of p53 as measured by RT-PCR in
CT or shP53 cells after activation of MYC by OHT
for 3 days.
(D) Typical phase contrast and green fluorescence
(GFP) of live shP53 cells 4 days postinfection with
or without OHT as indicated.
(E) Percent of CT or shP53 GFP cells expressing
the terminal differentiation marker keratin K1 after
addition of OHT for 5 days, as determined by
immunofluorescence.
(F) Immunofluorescence for involucrin (green) of
CT or shP53 cells, 5 days after addition of OHT.
Nuclear DNA by DAPI (blue).
(G) Percent of CT or shP53 cells expressing in-
volucrin (Invol) after addition of OHT for 5 days, as
determined by flow-cytometry.
Error bars are SEM of duplicate samples of
representative experiments. *p < 0.05. Scale bar,
50 mm.population decreased in G1/diploidy and increased in polyploidy
(with frequent multinucleation), while the G2/M fraction remained
basically unchanged (Figures 4B, S2B, and S2C). All in all, we
found no great increase of S phase or proliferative mitosis
3 days after inhibition of p53, but a cell cycle shift toward1352 Cell Reports 9, 1349–1360, November 20, 2014 ª2014 The Authorspolyploidy as a result of mitotic bypass
or mitotic slippage shP53 (re-replication
or endoreplication in the absence of cell
division; Andreassen and Margolis,
1994; red arrow in Figure 4B and Figure
S2B). Consistently, there was a transient
accumulation of mitotic markers cyclin A
and cyclin B and the metaphase marker
P-H3 (Figures 3B, 4C, S3A, and S3B;
Movies S2, S4, S5, and S6), an increase
of cells expressing postmitotic keratin
K1 (Figure 4C), and an accumulation of
cyclin E that typically associates with ker-
atinocyte mitotic slippage (Figures 3B
and S3C; Zanet et al., 2010; Freije et al.,
2012). Concomitantly, a high frequency
of cells displayed striking accumulation
of cytoplasmic cyclin A or B (Figures 4C
and S3A; Movie S2). Inhibition of shP53
induced a shorter form of cyclin A (Fig-
ure 3B), likely inactive (Kaufmann et al.,2001; Wang et al., 2012), even more upon overactivation of
MYC (Figure S3D). Timely degradation of cyclins A and B is
required for exit from mitosis, and their cytoplasmic accumula-
tion is likely to associate with defective mitosis (Murray, 2004;
Zanet et al., 2010; Rosa-Garrido et al., 2012).
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Figure 3. Disruption of Endogenous p53 in Human Keratinocytes
Causes Replication Stress
(A) Expression of p53, its target p21, and p63 in HK infected with CTGFP (CT)
or with shP53 as indicated, untreated or treated with the genotoxic drug
doxorubicin (DOXO) for 24 hr. Bar histogram represents quantitation of
western blots normalized to GAPDH (GDH).
(B) Western blot for the cell cycle regulators indicated in CT or shP53 cells, 2 or
3 days postinfection; Cyc, cyclin. See also Figure S2A.
(C) Bar histogram shows expression of p53 in CT or shP53 cells as measured
by RT-PCR 2 days postinfection. See also Figure S2A.
(D) Double immunostaining for p53 (red) and gH2AX (green) 3 days post-
infection. Note that cells with low p53 tend to accumulate DNA damage
(arrows) and vice versa. Nuclear DNA by DAPI (blue). See also Figure S5. Scale
bar, 50 mm.
(E) Distribution histogram shows number of foci of gH2AX per nucleus, as
scored by immunofluorescence as in Figure 3D and image analyses. Left bar
Cell ReAs a consequence of failure to exit cytokinetic mitosis, loss of
p53 did not result in increased proliferation but did result in a sig-
nificant loss of clonogenic potential (Figure 4D). Cells expressing
shP53 were impaired especially in the generation of large col-
onies that are founded by the great potential of stem cells (Jones
and Watt, 1993). The loss of clonogenic potential by inactivating
p53 did not involve detectable apoptosis (absence of a sub-G1
DNA peak; Figure S2B). Accumulation of mitotic markers and
metaphase figures, loss of the capacity to divide, polyploidy,
BrdU incorporation by polyploid cells, and multinucleation alto-
gether indicate that loss of p53 in keratinocytes leads to mitotic
slippage, by which cells enter mitosis but fail to divide (see also
below).
Loss of p53 Promotes Squamous Differentiation
Mitosis failure in keratinocytes triggers terminal differentiation,
and cell cycle stress triggers this mitosis-differentiation check-
point (Zanet et al., 2010; Freije et al., 2012; Gandarillas, 2012).
We explored whether loss of p53 triggered this response, thus
explaining the observed loss of clonogenic potential. As shown
in Figures 5A–5C and S4, inhibition of p53 strikingly induced
the squamous differentiation markers involucrin, keratin K1
(see also Figure 4C), keratin K10, and filaggrin as well as cell-
size increase and morphological changes typical of terminal dif-
ferentiation. As a consequence, cells with low levels of p53 were
found to stratify and detach at a higher rate than control cells in
confocal analyses (Figure S5A; Movie S3). The time-lapse videos
also showed that HKshP53 stressed and accumulated in mitosis
attempting to divide (Movies S4, S5, and S6). To better study the
effect on differentiation, we placed cells in a high-calcium me-
dium that allows stratification closely resembling the process
in human epidermis (Rheinwald, 1989). Cells expressing the
GFP marker displayed very low levels of p53, stratified, and
detached (Movies S3 and S7). Shed cells were counted in the
culture medium showing that inactivation of p53 produced a
higher rate of desquamation (Figure 5D). Consistently, within un-
selected mixed cultures, 5–6 days after delivery of shP53, cells
with detectable levels of p53 and low levels of gH2AX had
repopulated the basal proliferative layer (Figure S5B). This
further indicates that cells expressing p53 are more proliferative.
Maintaining the proliferative potential might be a keratinocyte
stem cell p53 function, since in parallel experiments, inhibition
of p53 led to increased proliferation and impaired senescence
in pluripotent mesenchymal stem cells (Figure S6).
Inactivation of a Temperature-Sensitive p53 Mutant
Protein PromotesDifferentiation, whereas Its Activation
Attenuates It
Often, in skin tumors and in patients with Li-Fraumeni syndrome,
mutated p53 coexists with the normal allele. In this context, inac-
tive p53 mutants can have a dominant-negative effect by dis-
rupting the function of the endogenous protein (Hann andhistogram shows percentage of positive gH2AX cells as quantitated by flow
cytometry. Right bar histogram shows the mean gH2AX intensity per cell as
measured by flow cytometry in the whole population.
Error bars are SEM of duplicate samples of representative experiments. *p <
0.05.
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Figure 4. Disruption of Endogenous p53 in
Human Keratinocytes Causes Mitotic Slip-
page and Loss of Clonogenic Potential
(A) Percent of total or polyploid (polyp) HK infected
with shP53 undergoing DNA synthesis (BrdU+) for
the periods of time postinfection indicated, as
quantitated by flow cytometry and normalized to
HK infectedwithCTGFP (CT). See also Figure S2B.
(B) Percent of cells in the G1/S (2N), G2/M (4N), or
polyp phases of the cell cycle in CT (gray) or
shP53 (light red) cells 3 days postinfection, as
determined by flow cytometry. Red arrow shows
the shift of shP53 cells toward polyploidy, a
consequence of mitotic slippage. See also Fig-
ures S2B and S2C.
(C) Double immunostaining for K1 (green, arrow
heads) and mitotic cyclin B (CycB, red; arrows).
Nuclear DNA by DAPI (blue). shP53 cells dis-
played frequent accumulation of cytoplasmic cy-
clin B (cytopl+), and scoring is shown in the bar
histogram. See also Movie S2.
(D) Clonogenic capacity of CT or shP53 cells
(10,000 cells plated 3 days postinfection). Bar and
circle histograms show the number (bars) and
percent (circles) of actively shP53 growing col-
onies (light gray) versus small abortive, differenti-
ated colonies (dark gray).
Error bars are SEM of duplicate (A–C) or triplicate
(D) samples of representative experiments. *p <
0.05.Lane, 1995; Blagosklonny, 2000; Sigal and Rotter, 2000; Lee
et al., 2012). To mimic this condition, we have overexpressed
in epidermal keratinocytes (HKp53ts) a well-characterized
mutant form of p53 (p53ts), whose conformation state can be
regulated by temperature (Michalovitz et al., 1990). At 32C,
p53ts displays the wild-type conformation, whereas at 39C, it
adopts an inactive conformation and can thus behave as a domi-
nant-negative mutant. It is well established that active p53 is
rapidly degraded due to an autoregulatory feedback loop with
MDM2, whereas the inactive protein stabilizes and accumulates
(Haupt et al., 1997). Consistently, HKp53ts expressed higher
levels of p53 at 32C than control cells, but the protein accumu-
lated further at 39C as it adopted the inactive conformation (an-
tigen pab240 positive; Figures 6A, 6B, and S7A; Gannon et al.,
1990; Michalovitz et al., 1990). In addition, while p53 was absent
from suprabasal HKp53ts at 32C, as the endogenous protein, it
accumulated in suprabasal involucrin-positive cells at 39C
(Figure 6B and S7A). This further indicated that the protein was
inactivated at 39C.
Inactivation of p53ts in human keratinocytes by the 39C tem-
perature switch resulted in increased differentiation monitored
as high light scatter and expression of the suprabasal markers in-
volucrin and keratin K16 (Figures 6B, 6C, and S7B, and S7C).
Conversely, inducing the active conformation of p53ts at 32C
retained keratinocytes in the proliferative compartment as deter-1354 Cell Reports 9, 1349–1360, November 20, 2014 ª2014 The Authorsmined by an increased proportion of cells
with basal-like low-scatter parameters
and decreased expression of the supra-
basal markers (Figures 6B, 6C, S7B,and S7C). Loss or gain of cell cycle control by inactivation or
activation of p53 was reflected in the increase or decrease of
hyperproliferative suprabasal K16 at 39C or 32C, respectively.
As observed after suppressing endogenous p53 by shRNA, the
inactive form of p53ts caused binucleation, increased nuclear
size and gH2AX-associated DNA damage (Figures 6B and
S7A, S7D, and S7E; arrows), and reduced the clonogenic poten-
tial of the stem cell compartment once cells were returned to
37C (Figure 6D). No additional gains of function were observed.
DISCUSSION
Role of p53 in Human Keratinocytes
Altogether, our results demonstrate a human epidermal cell
response to loss of p53 function consistent with an oncogene-
induced differentiation checkpoint (OID). Keratinocytes lacking
p53 differentiated, as determined by the expression of various
differentiation markers, morphological changes, and loss of pro-
liferative capacity. This process was preceded by mitosis de-
fects, suggesting that endogenous p53 interferes with the initia-
tion of epidermal differentiation by retaining cells within the
proliferative compartment. p53 might cause this by two mecha-
nisms (Figure 7): (1) by holding cells in the G1 and G2/M phases
of the cell cycle and ensuring efficient DNA repair, or (2) by
opposing cyclin E function. Interestingly, p53 has been proposed
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Figure 5. Loss of Endogenous p53 in Human
Keratinocytes Triggers Terminal Differenti-
ation, Stratification, and Shedding
(A) Dot plots show flow-cytometry analyses for
GFP (green) versus light scatter (SSC-A; left) or
involucrin (invol, right) of HK infected with shP53.
Bar histograms show percent of differentiating
(high light scatter; diff. in dot plot) or Invol positive
(i+ in dot plot) cells in the GFP (+) or non-GFP ()
populations, as indicated. CT, cells infected with
control vector. See also Figure S4A.
(B) Double immunostaining for GFP (green) and
Invol (red) 5 days postinfection of HK with CTGFP
(CT) or shP53 as indicated; nuclear DNA by DAPI
(blue). Bar histograms show percentage of cells
positive for Invol and K1 (flow cytometry), or K10
(immunofluorescence) in shP53 cells relative to CT
cells. Scale bar, 50 mm. See also Figure S4.
(C) Expression of differentiation markers K1, ker-
atin K10, filaggrin (Fil), and Invol, as determined by
RT-PCR in shP53 cells relative to CT cells 2 days
postinfections.
(D) Snap frames from Movies S4 and S6 showing
the accumulation of shP53 cells in mitosis (arrows)
5 days postinfection. Nuclear DNA by NucBlue
(blue). Amplified insets show a cell blocked in
metaphase (bottom panel: DNA only). See also
Movies S4, S5, and S6. Bar histogram shows
percent of shP53 cells shed into the medium,
relative to control cells.
Error bars are SEM of duplicate samples of repre-
sentative experiments. *p < 0.05. Scale bars repre-
sent 50 mm (B and D) or 10 mm (small insets in D).to constitute a barrier against hyperactivation of cyclin E/cdk2
(Minella et al., 2002), and cyclin E mediates MYC-induced kera-
tinocyte cell cycle stress and differentiation (Freije et al., 2012).
Loss of p53 may thus allow cyclin E/cdk2 (ergo MYC) full power
to trigger the differentiation response. This would mitigate the
cell cycle stress/OID response and the cell division block that
triggers squamous differentiation (Zanet et al., 2010; Freije
et al., 2012; Gandarillas, 2012).
The results provide insight into the enigmatic role of p53 in
epidermal homeostasis with implications in stem cell regulation.
First, they show that p53 is dispensable for the epidermal differ-
entiation signal. Second, by promoting the correct timing of the
cell cycle checkpoints and avoiding mitotic slippage, p53 ap-
pears to protect the proliferative capacity of epidermal stem cells
(Figure 7). Consistent with this model, p53 is downregulated as
epidermal differentiation initiates (see Dazard et al., 2000 and
references therein), and its overexpression inhibited growth
and squamous differentiation markers in cell-reconstituted
epidermis (Woodworth et al., 1993). p53 was also dispensable
for the differentiation signal caused by overactivation of MYC.
This signal might be triggered in cells accumulating irreparable
DNA damage (strand breaks) and escaping the protective roleCell Reports 9, 1349–1360, Noof p53 (Figure 7), since it was enhanced
by inhibition of the DNA repair ATM
pathway. Interestingly, the differentiation
signal was also enhanced in normal kera-tinocytes by inhibition of the DNA repair poly-(ADP-ribose)-
polymerase.
Protecting the proliferative potential of stemcells fromdifferen-
tiation might be a keratinocyte function of p53, since in other cell
types, it promotesapoptosis, senescence, or evendifferentiation.
In this study, shP53 prolonged the lifespan of human pluripotent
mesenchymal stem cells. As mentioned above, we have shown
that MYC in keratinocytes promotes differentiation, while in other
cells it promotes proliferation. As we have suggested for MYC
(Gandarillas, 2012; Mun˜oz-Alonso et al., 2012), the cell-growth
deregulation that follows p53 loss might trigger differentiation in
cells where this process is associated with cellular growth. Para-
doxical inhibition of senescence by p53 has also been reported
(Demidenko et al., 2010). Conversely, p53 has been shown to
induce apoptosis in keratinocytes after acute damage caused
by sunburn (Ziegler et al., 1994). p53 might thus play a dual role
in epidermal survival by keeping proliferative cells ‘‘healthy’’ and
inducing cell death of severely damaged cells.
Implications into Skin Homeostasis and Cancer
Our fluorescent confocal and video analyses on mixed
(GFP and no-GFP cells) stratifying cultures showed thatvember 20, 2014 ª2014 The Authors 1355
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Figure 6. A Mutant Inactive Conformation of
p53 Induces Keratinocyte Differentiation
and Reduces the Great Proliferative Poten-
tial Cell Compartment
(A) Detection of p53 by western blotting in kerati-
nocytes expressing control vector (CT) or the
temperature-sensitive mutant p53 (p53ts) 48 hr
after the temperature switch to 32C or 39C
as indicated. Bar histogram show quantitation of
p53 western blots normalized to GAPDH (GDH).
Note that p53 accumulates at 39C (inactive
conformation).
(B) Top: immunofluorescence for p53 (green) on
p53ts cells as in (A); Bottom: double immunofluo-
rescence for involucrin (Invol, green) and p53 (red)
on p53ts cells 4 days after the temperature switch.
Note the binucleate differentiating p53ts cells that
accumulate p53 at 39C (arrows). Nuclear DNA by
DAPI (blue). See also Figure S7A. Scale bar, 50 mm.
(C) Representative flow cytometry for the expres-
sion of Invol (top) or the hyperproliferative marker
keratin K16 (bottom) in p53ts cells 6 days after the
temperature switch, as indicated. Bar histograms
show percent of morphologically differentiated
(high scatter) cells or cells positive for Invol or K16
as indicated, normalized to CT cells; quantitation of
positive cells by the gates indicated on the histo-
grams (+), as determined by a negative isotype
antibody control (dotted line; CD8). See also
Figure S7B.
(D) Clonogenic capacity of p53ts cells plated
5 days after the 39C temperature switch. A total of
2,500 proliferative cells were plated. Bar and circle
histogram show number (bars) or percent (circles)
of actively shP53 growing colonies (light gray)
versus small abortive, differentiated colonies (dark
gray).
Error bars are SEM of duplicate (C) or triplicate (D)
samples of representative experiments. *p < 0.05.p53-defective keratinocytes had a higher tendency to stratify
and detach than the normal cells. It is intriguing that the
absence of p53 did not cause apparent physiological defects
in mouse skin in vivo (Donehower et al., 1992; Martı´nez-Cruz
et al., 2008). This, in part, might be due to compensatory mech-
anisms. Also, the in vivo niche might rescue the proliferative ca-
pacity of stem cells. For instance, lack of MYC renders mouse
keratinocytes unable to proliferate in vitro, but they can form an
epidermis in vivo (Zanet et al., 2005). Interestingly, however, the
specific ablation of p53 in mouse epidermis caused mitotic de-
fects (Martı´nez-Cruz et al., 2009). In addition, our model for
mitosis-induced differentiation is that keratinocytes undergoing
a prolonged arrest in mitosis are pushed to stratify and differen-
tiate by other more proliferative and more adherent neighbor
cells (Gandarillas, 2012). This might thus involve competition
phenomena. Within these lines, it is interesting that in mouse
epidermis, p53 mutant clones are growth limited by normal1356 Cell Reports 9, 1349–1360, November 20, 2014 ª2014 The Authorsadjacent clones unless the skin is UV
irradiated (Zhang et al., 2001).
Altogether, our results have implica-
tions into the mechanisms leading toepithelial skin cancer (mainly SCC), in which p53 is frequently
mutated. Disruption of p53, however, does not seem to be an
initiating event in this malignancy, since mice lacking p53 die
around 4–6 months, mainly of thymic lymphoma, and do not
develop early skin tumors (Donehower et al., 1992). Consistently,
epidermal-specific p53 knockout mice develop spontaneous
tumors from 5 months onward (Martı´nez-Cruz et al., 2008).
This is also consistent with humans usually developing skin car-
cinomas at an old age. In addition, p53 knockout mice are not
more susceptible to chemically induced skin carcinogenesis
(Donehower et al., 1992; Kemp et al., 1993). Within similar lines,
Li-Fraumeni patients having onemutant p53 allele do not display
a higher rate of skin carcinomas (Malkin et al., 1990; Srivastava
et al., 1990). Altogether, these observations suggest that
the epidermis has mechanisms to be protected from p53 muta-
tions. This is further supported by the well-documented pres-
ence of frequent clones or ‘‘columns’’ of p53 mutant cells in
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Figure 7. Model for the Role of p53 in Proliferation and Differentia-
tion of Human Epidermal Keratinocytes
p53 would hold cells, allowing DNA repair. Cells with successful repair would
re-enter the proliferative compartment, and cells with irreparable levels of DNA
damage would undergo mitosis slippage, terminal differentiation, stratifica-
tion, and shedding. p53 would protect the proliferative potential of stem
cells (left), and its loss of function would lead to loss of proliferative potential
(right).sun-exposed asymptomatic skin that do not seem to lead to
cancer (Jonason et al., 1996; Ren et al., 1997; le Pelletier et al.,
2001). Our results herein provide a mechanism explaining these
observations. Loss of cells with inactive p53, by stratification and
shedding due to unrepaired DNA damage, may explain how the
skin protects itself from mutations hitting this tumor suppressor.
Precancerous keratinocytes would be removed via squamous
differentiation, therefore avoiding clinical impact.
Although loss of p53 does not sensitize the skin to early
tumorigenesis, it accelerates cancer progression (Kemp et al.,
1993; Bornachea et al., 2012). Interestingly, genomic instability
appears to contribute to the spontaneous tumors developed
in p53 knockout mouse epidermis (Martı´nez-Cruz et al.,
2009). In addition, mouse skin deficient in p53 or overexpress-
ing a mutant form develops tumors more frequently when
UV irradiated (Li et al., 1995; Jiang et al., 1999). UV causes ker-
atinocytes to arrest in G2 (Pavey et al., 2001). Our results sup-
port a model that might reconcile these observations. In our
experiments, inhibition of p53 impaired efficient G2 arrest, re-
sulting in mitotic slippage and terminal differentiation, thereby
suppressing cell division (Figure 7). Additional alterations coop-
erating with inactivation of p53 might hit the control of mitosis
and bypass the proliferative block. This would allow p53-
mutated cells to escape terminal differentiation and expulsion
and divide in spite of a high genomic instability context caused
by genetic damage, thus promoting malignant clones to
appear.
EXPERIMENTAL PROCEDURES
Cell Culture, Plasmids, Viral Infections, and Treatments
Ethical permission for this study was requested, approved, and obtained from
the Ethical Committee for Clinical Research of Cantabria Council, Spain. In all
cases, human tissue material discarded after surgery was obtained with writ-
ten consent presented by clinicians to the patients, and it was treated
anonymously.
Primary keratinocytes were isolated from neonatal human foreskin and
cultured in the presence of a mouse fibroblast feeder layer (inactivated by
mitomycin C) in Rheinwald FAD medium as described previously (10% serum
and 1.2 mM Ca+2; Rheinwald, 1989; Gandarillas and Watt, 1997). Low pas-
sages (one to five) of keratinocytes from four different individuals were utilized.Cell ReFor gene delivery in primary keratinocytes the following viral constructs
driven by viral constitutive promoters were used. Retroviral constructs
were pBabe empty vector, pBabe-MYCER (Littlewood et al., 1995; Gandar-
illas and Watt, 1997; MYC fusion protein with the ligand binding domain of a
mutant estrogen receptor that responds to 4-OH-hydroxytamoxifen; OHT),
or pBabe-p53Val135 (p53ts; kindly provided by M. Oren, Weizmann Institute,
Revohot, Israel) carrying a mutant p53 whose conformation can be regulated
by a temperature shift (wild-type at 32C, inactive at 39C; Michalovitz et al.,
1990). All pBabe constructs carried puromycin resistance and were delivered
by cell infection, and cells were selected as described previously (Freije
et al., 2012). Lentiviral constructs were control plKO1 (CT; Sigma-Aldrich),
control GFP pLVTHM (CTGFP), and three constructs expressing shRNA
specific against p53: the GFP expressing vector pLVUH-shp53 (shP53)
and two non-GFP constructs pLKO1-p53-shRNA-427 (shP53-427; Addgene;
Kim et al., 2007) and pLKO1-p53-shRNA-941 (shP53-941; Addgene; Kim
et al., 2007). More details can be found in Supplemental Experimental
Procedures.
For delivery of shRNA expressing constructs in primary human keratino-
cytes, two alternative optimized methods of infection were used giving
‘‘low’’ (25%–35%) or ‘‘high’’ (80%–90%) efficiency. Cells were then placed
on low calcium or high calcium media depending on the experiment. See Sup-
plemental Experimental Procedures for method details.
MYCERwas activated by addition of 100 nMOHT (Sigma-Aldrich) to the cul-
ture medium for the periods of time indicated. Keratinocytes were grown at
37C and 5% CO2 except for induction of active or inactive conformations of
p53ts, when the temperature was shifted to 32C and 39C, respectively, for
the periods of time indicated.
Primary keratinocytes were treated for 6 days with the ATM inhibitor
KU55933 (10 mM; Tocris Bioscience) or with the PARP inhibitor NU1025
(200 mM; Millipore) for 24 or 72 hr. Parallel control cultures were always sub-
jected to the DMSO vehicle only.
For clonogenicity assays, 15,000 keratinocytes grown in low-calcium me-
dium or 2,500 grown in high-calcium FADmediumwere plated per T6 well trip-
licates and cultured in FAD medium. About 10 days later, the cultures were
stained with rhodanile blue as described previously (Jones and Watt, 1993).
This dye colors keratinocytes pink (darker the more differentiated) and feeder
fibroblasts purple.
Cell Shedding
Quantitation of cell shedding was measured by counting cells detached into
the culture medium. Data were obtained from duplicate samples and normal-
ized to controls.
Antibodies
Primary and secondary antibodies utilized in this study are listed in Supple-
mental Experimental Procedures.
Flow Cytometry
Keratinocytes were harvested, fixed, and stained for BrdU and DNA (propi-
dium iodide [PI]) or for involucrin and analyzed by flow cytometry as described
in Supplemental Experimental Procedures. All antibody stainings were
controlled by the use of a similar concentration of isotype-negative immuno-
globulins (mouse anti-CD8 or rabbit serum). A total of 10,000 events were
gated and acquired in list mode for every sample except for some GFP-posi-
tive analyses, when 50,000 cells were acquired. In order to gate out cell aggre-
gates, the area of the fluorescent pulse of PI (DNA content; PE-A) was plotted
versus the width of the fluorescent pulse (PE-W).
Immunofluorescence and Confocal Microscopy
Keratinocytes were grown on glass coverslips, fixed and stained as previously
described (Freije et al., 2012). After washing with PBS, coverslips were stained
with 0.1 mg/ml DAPI, mounted with ProLong Gold Antifade Reagent (Life Tech-
nologies), and visualized and photographed under AxioVision Zeiss fluores-
cent microscopy. z stack 3D digital images were reconstructed after frame
collection by confocal microscopy (Nikon A1R, 203 numerical aperture [NA]
0.75) and processed by NIS Elements software (AR, 3.2 64 bits; Nikon) as indi-
cated in the supplemental movie legends.ports 9, 1349–1360, November 20, 2014 ª2014 The Authors 1357
Whole-Cell Extracts and Western Blotting
Cells were washed twice with PBS and incubated for 30 min on ice in lysis
buffer as described previously (Freije et al., 2012). Supernatant concentrations
were determined using the Qubit protein assay kit (Life Technologies). For
western blot analysis, 80 mg of cell extracts was separated by SDS-PAGE
(10% or 12%) and transferred to nitrocellulose membranes. After blocking
and incubating with the primary antibodies, the membranes were subjected
to secondary antibodies and subjected to enhanced chemiluminescence sub-
strate (SuperSignalTM West Femto, Pierce), following the supplier’s protocol,
and analyzed with an Odyssey scanner (Li-Cor) or C-Digit scanner (Li-Cor).
RT-PCR
Total RNAwas isolated using NucleoSpin RNA (Macherey-Nagel) according to
the manufacturer’s instructions. A total of 1 mg of total RNA was reverse tran-
scribed with the iScript cDNA synthesis kit (Bio-Rad) in a 20 ml reaction for
30 min at 42C. The cDNAs (1 ml) were amplified by real-time PCR (Bio-Rad
iQ SYBR green supermix) and normalized to b-actin mRNA levels. Primers uti-
lized in this study are listed in Supplemental Experimental Procedures.
Time-Lapse Videos
For Movies S4, S5, and S6, keratinocytes 4 days postinfection with a control
(CT) or non-GFP-expressing shP53 construct (shP53-427) were treated
with NucBlue Live ReadyProbes Reagent (Life Technologies) and filmed by
time-lapse imaging for 24 hr, photographed every 7 min. For Movie S7,
keratinocytes 5 days postinfection with shP53-GFP construct were filmed by
time-lapse imaging for 11 hr, photographed every 10 min. In all cases,
phase-contrast and green- or blue-fluorescence images were obtained by an
epifluorescencemicroscope (NIKON Ti; 103NA 0.30) by anORCAR2 camera.
Statistical Analyses
Data sets were compared using an unpaired Student’s t test. A p value of less
than 0.05 was considered statistically significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and seven movies and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2014.10.012.
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